Top

Published in:

01-12-2011 | Original Paper

Roles of Bone Marrow Cells in Skeletal Metastases: No Longer Bystanders

Authors: Serk In Park, Fabiana N. Soki, Laurie K. McCauley

Published in: Cancer Microenvironment | Issue 3/2011

Abstract

Bone serves one of the most congenial metastatic microenvironments for multiple types of solid tumors, but its role in this process remains under-explored. Among many cell populations constituting the bone and bone marrow microenvironment, osteoblasts (originated from mesenchymal stem cells) and osteoclasts (originated from hematopoietic stem cells) have been the main research focus for pro-tumorigenic roles. Recently, increasing evidence further elucidates that hematopoietic lineage cells as well as stromal cells in the bone marrow mediate distinct but critical functions in tumor growth, metastasis, angiogenesis and apoptosis in the bone microenvironment. This review article summarizes the key evidence describing differential roles of bone marrow cells, including hematopoietic stem cells (HSCs), megakaryocytes, macrophages and myeloid-derived suppressor cells in the development of metastatic bone lesions. HSCs promote tumor growth by switching on angiogenesis, but at the same time compete with metastatic tumor cells for occupancy of osteoblastic niche. Megakaryocytes negatively regulate the extravasating tumor cells by inducing apoptosis and suppressing proliferation. Macrophages and myeloid cells have pro-tumorigenic roles in general, suggesting a similar effect in the bone marrow. Hematopoietic and stromal cell populations in the bone marrow, previously considered as simple by-standers in the context of tumor metastasis, have distinct and active roles in promoting or suppressing tumor growth and metastasis in bone. Further investigation on the extended roles of bone marrow cells will help formulate better approaches to treatment through improved understanding of the metastatic bone microenvironment.

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Canc 3(6):453–458CrossRef

Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Canc Res 70(14):5649–5669. doi:10.1158/0008-5472.CAN-10-1040 CrossRef

Fidler IJ (2002) Critical determinants of metastasis. Semin Canc Biol 12(2):89–96. doi:10.1006/scbi.2001.0416 CrossRef

Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Canc Metastasis Rev 8(2):98–101

Ewing J (1928) Neoplastic diseases; a treatise on tumors. 3d ed rev. and enl., with 546 illustrations. edn. W.B. Saunders, Philadelphia, London

Geldof AA (1997) Models for cancer skeletal metastasis: a reappraisal of Batson’s plexus. Anticancer Res 17(3A):1535–1539PubMed

Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306):893–895CrossRefPubMed

Hart IR, Fidler IJ (1980) Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Canc Res 40(7):2281–2287

Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B (1984) Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Br Med J (Clin Res Ed) 288(6419):749–751CrossRef

10.

Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B (1984) Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Canc Res 44(8):3584–3592

11.

Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL (2006) Metastatic patterns in adenocarcinoma. Cancer 106(7):1624–1633. doi:10.1002/cncr.21778 CrossRefPubMed

12.

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5):578–583CrossRefPubMed

13.

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Canc 2(8):584–593. doi:10.1038/nrc867 CrossRef

14.

Roodman GD (2004) Mechanisms of bone metastasis. New Engl J Med 350(16):1655–1664. doi:10.1056/NEJMra030831 CrossRefPubMed

15.

Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ (2000) Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Canc Res 6(3):1038–1045

16.

Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Canc 11(6):411–425. doi:10.1038/nrc3055 CrossRef

17.

Casimiro S, Guise TA, Chirgwin J (2009) The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310(1–2):71–81. doi:10.1016/j.mce.2009.07.004 CrossRefPubMed

18.

Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Investig 98(7):1544–1549. doi:10.1172/JCI118947 CrossRefPubMed

19.

Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Investig 103(2):197–206. doi:10.1172/JCI3523 CrossRefPubMed

20.

Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK (2009) A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Canc Res 69(4):1685–1692. doi:10.1158/0008-5472.CAN-08-2164 CrossRef

21.

Liao J, Li X, Koh AJ, Berry JE, Thudi N, Rosol TJ, Pienta KJ, McCauley LK (2008) Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Canc 123(10):2267–2278. doi:10.1002/ijc.23602 CrossRef

22.

Liao J, McCauley LK (2006) Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Canc Metastasis Rev 25(4):559–571. doi:10.1007/s10555-006-9033-z CrossRef

23.

Bergfeld SA, DeClerck YA (2010) Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Canc Metastasis Rev 29(2):249–261. doi:10.1007/s10555-010-9222-7 CrossRef

24.

Ara T, Declerck YA (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Canc 46(7):1223–1231. doi:10.1016/j.ejca.2010.02.026 CrossRef

25.

Paul WE (1999) Fundamental immunology, 4th edn. Lippincott-Raven, Philadelphia

26.

Schermer S (1967) The blood morphology of laboratory animals, 3rd edn. Davis, Philadelphia

27.

Travlos GS (2006) Normal structure, function, and histology of the bone marrow. Toxicol Pathol 34(5):548–565. doi:10.1080/01926230600939856 CrossRefPubMed

28.

Shirota T, Tavassoli M (1991) Cyclophosphamide-induced alterations of bone marrow endothelium: implications in homing of marrow cells after transplantation. Exp Hematol 19(5):369–373PubMed

29.

Shirota T, Tavassoli M (1992) Alterations of bone marrow sinus endothelium induced by ionizing irradiation: implications in the homing of intravenously transplanted marrow cells. Blood Cell 18(2):197–214

30.

Weiss L, Geduldig U (1991) Barrier cells: stromal regulation of hematopoiesis and blood cell release in normal and stressed murine bone marrow. Blood 78(4):975–990PubMed

31.

Tavassoli M, Hardy CL (1990) Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 76(6):1059–1070PubMed

32.

Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH (1998) Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med 188(3):465–474CrossRefPubMed

33.

Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD (1998) Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci U S A 95(24):14423–14428CrossRefPubMed

34.

Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283(5403):845–848CrossRefPubMed

35.

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56. doi:10.1038/35065016 CrossRefPubMed

36.

Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Canc Res 62(6):1832–1837

37.

Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J (2010) CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Canc Metastasis Rev 29(4):709–722. doi:10.1007/s10555-010-9256-x CrossRef

38.

Jung Y, Wang J, Song J, Shiozawa Y, Havens A, Wang Z, Sun YX, Emerson SG, Krebsbach PH, Taichman RS (2007) Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 110(1):82–90. doi:10.1182/blood-2006-05-021352 CrossRefPubMed

39.

Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS (2008) Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 105(2):370–380. doi:10.1002/jcb.21835 CrossRefPubMed

40.

Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Investig. doi:10.1172/JCI43414

41.

Okamoto R, Ueno M, Yamada Y, Takahashi N, Sano H, Suda T, Takakura N (2005) Hematopoietic cells regulate the angiogenic switch during tumorigenesis. Blood 105(7):2757–2763. doi:10.1182/blood-2004-08-3317 CrossRefPubMed

42.

Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146(4):1727–1736. doi:10.1210/en.2004-1211 CrossRefPubMed

43.

Lichtman MA, Chamberlain JK, Simon W, Santillo PA (1978) Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. Am J Hematol 4(4):303–312CrossRefPubMed

44.

Li X, Koh AJ, Wang Z, Soki FN, Park SI, Pienta KJ, McCauley LK (2011) Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. J Bone Miner Res 26(1):125–134. doi:10.1002/jbmr.204 CrossRefPubMed

45.

Kacena MA, Gundberg CM, Horowitz MC (2006) A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone 39(5):978–984. doi:10.1016/j.bone.2006.05.019 CrossRefPubMed

46.

Kacena MA, Nelson T, Clough ME, Lee SK, Lorenzo JA, Gundberg CM, Horowitz MC (2006) Megakaryocyte-mediated inhibition of osteoclast development. Bone 39(5):991–999. doi:10.1016/j.bone.2006.05.004 CrossRefPubMed

47.

Kacena MA, Shivdasani RA, Wilson K, Xi Y, Troiano N, Nazarian A, Gundberg CM, Bouxsein ML, Lorenzo JA, Horowitz MC (2004) Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res 19(4):652–660. doi:10.1359/JBMR.0301254 CrossRefPubMed

48.

Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE (2005) Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. Bone 36(5):812–819. doi:10.1016/j.bone.2004.12.006 CrossRefPubMed

49.

Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425(6960):841–846. doi:10.1038/nature02040 CrossRefPubMed

50.

Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T (1999) Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone 25(5):517–523CrossRefPubMed

51.

Ahmed N, Khokher MA, Hassan HT (1999) Cytokine-induced expansion of human CD34+ stem/progenitor and CD34 + CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts. Stem Cell 17(2):92–99. doi:10.1002/stem.170092 CrossRef

52.

Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R (2008) Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 3(11):e3627. doi:10.1371/journal.pone.0003627 CrossRefPubMed

53.

Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298–307. doi:10.1038/nature10144 CrossRefPubMed

54.

Nieswandt B, Hafner M, Echtenacher B, Mannel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Canc Res 59(6):1295–1300

55.

Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Investig 114(12):1714–1725. doi:10.1172/JCI22123 PubMed

56.

Gupta GP, Massague J (2004) Platelets and metastasis revisited: a novel fatty link. J Clin Investig 114(12):1691–1693. doi:10.1172/JCI23823 PubMed

57.

Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS, Roca H, Pienta KJ (2009) The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11(11):1235–1242PubMed

58.

Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9(7):556–562CrossRefPubMed

59.

Halin S, Rudolfsson SH, Van Rooijen N, Bergh A (2009) Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 11(2):177–186PubMed

60.

Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065–1073. doi:10.1189/jlb.0609385 CrossRefPubMed

61.

Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, Hosoi F, Shoda T, Nagata K, Osada H, Ono M, Kuwano M (2008) Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Canc Sci 99(8):1595–1602. doi:10.1111/j.1349-7006.2008.00880.x CrossRef

62.

Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196(3):254–265. doi:10.1002/path.1027 CrossRefPubMed

63.

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A (2008) Macrophage polarization in tumour progression. Semin Canc Biol 18(5):349–355. doi:10.1016/j.semcancer.2008.03.004 CrossRef

64.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0 CrossRefPubMed

65.

Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Canc Res 67(19):9417–9424. doi:10.1158/0008-5472.CAN-07-1286 CrossRef

66.

Roca H, Varsos Z, Pienta KJ (2008) CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 283(36):25057–25073. doi:10.1074/jbc.M801073200 CrossRefPubMed

67.

Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ (2009) CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284(49):34342–34354. doi:10.1074/jbc.M109.042671 CrossRefPubMed

68.

Zhang J, Lu Y, Pienta KJ (2010) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Canc Inst 102(8):522–528. doi:10.1093/jnci/djq044 CrossRef

69.

Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Canc Res 66(23):11238–11246. doi:10.1158/0008-5472.CAN-06-1278 CrossRef

70.

Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Canc Res 56(20):4625–4629

71.

Hildenbrand R, Dilger I, Horlin A, Stutte HJ (1995) Urokinase and macrophages in tumour angiogenesis. Br J Canc 72(4):818–823CrossRef

72.

Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR (1994) Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Canc 56(6):777–782CrossRef

73.

Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17(14):2115–2117. doi:10.1096/fj.03-0329fje PubMed

74.

MacMicking J, Xie QW, Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323–350. doi:10.1146/annurev.immunol.15.1.323 CrossRefPubMed

75.

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Canc 4(1):71–78. doi:10.1038/nrc1256 CrossRef

76.

Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. doi:10.1016/j.cell.2010.03.014 CrossRefPubMed

77.

Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Canc Res 66(2):605–612. doi:10.1158/0008-5472.CAN-05-4005 CrossRef

78.

Alexander K, Chang M, Maylin E, Kohler T, Muller R, Wu A, Van Rooijen N, Sweet M, Hume D, Raggatt L, Pettit A (2011) Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res 26(7):1517–1532. doi:10.1002/jbmr.354 CrossRefPubMed

79.

Chang MK, Raggatt LJ, Alexander KA, Kuliwaba JS, Fazzalari NL, Schroder K, Maylin ER, Ripoll VM, Hume DA, Pettit AR (2008) Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol 181(2):1232–1244PubMed

80.

Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl J Med 315(26):1650–1659. doi:10.1056/NEJM198612253152606 CrossRefPubMed

81.

Zumsteg A, Christofori G (2009) Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol 21(1):60–70. doi:10.1097/CCO.0b013e32831bed7e CrossRefPubMed

82.

Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Canc 8(8):618–631. doi:10.1038/nrc2444 CrossRef

83.

Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M (2010) Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 176(4):1564–1576. doi:10.2353/ajpath.2010.090786 CrossRefPubMed

84.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13(7):828–835. doi:10.1038/nm1609 CrossRefPubMed

85.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. doi:10.1038/nri2506 CrossRefPubMed

86.

Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Canc Res 68(8):2561–2563. doi:10.1158/0008-5472.CAN-07-6229 CrossRef

87.

Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Canc Cell 6(4):409–421. doi:10.1016/j.ccr.2004.08.031 CrossRef

88.

Yang L, Edwards CM, Mundy GR (2010) Gr-1 + CD11b + myeloid-derived suppressor cells (MDSCs): formidable partners in tumor metastasis. J Bone Miner Res 25(8):1701–1706. doi:10.1002/jbmr.154 CrossRefPubMed

89.

Kim SJ, Kim JS, Papadopoulos J, Wook Kim S, Maya M, Zhang F, He J, Fan D, Langley R, Fidler IJ (2009) Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol 174(5):1972–1980. doi:10.2353/ajpath.2009.080819 CrossRefPubMed

90.

Shojaei F, Zhong C, Wu X, Yu L, Ferrara N (2008) Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18(8):372–378. doi:10.1016/j.tcb.2008.06.003 CrossRefPubMed

91.

Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Canc Cell 13(3):193–205. doi:10.1016/j.ccr.2007.11.032 CrossRef

92.

Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E (1997) Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 62(3):397–400PubMed

93.

Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Canc Cell 13(1):23–35. doi:10.1016/j.ccr.2007.12.004 CrossRef

94.

ASBMR 29th Annual Meeting (2007) J Bone Miner Res 22(S1):s2–s51. doi:10.1002/jbmr.5650221402

95.

Zhuang J, Yang L, Lwin ST, Edwards CM, Edwards JR, Mundy GR (2008) Osteoclasts in myeloma are derived from Gr-1 + CD11b + myeloid immune suppressor cells of the bone marrow niche in vivo. ASH Annu Meet Abstr 112(11):736

96.

Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP (2007) Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Canc Res 67(23):11438–11446. doi:10.1158/0008-5472.CAN-07-1882 CrossRef

97.

Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Lee CH, Sud S, Pienta KJ, Krebsbach PH, Taichman RS (2010) Erythropoietin couples hematopoiesis with bone formation. PLoS One 5(5):e10853. doi:10.1371/journal.pone.0010853 CrossRefPubMed

98.

Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ (2009) Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460(7252):259–263. doi:10.1038/nature08099 CrossRefPubMed

99.

Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Canc Metastasis Rev 25(4):521–529. doi:10.1007/s10555-006-9036-9 CrossRef

100.

Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827. doi:10.1038/nature04186 CrossRefPubMed

Title: Roles of Bone Marrow Cells in Skeletal Metastases: No Longer Bystanders
Authors: Serk In Park
Fabiana N. Soki
Laurie K. McCauley
Publication date: 01-12-2011
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 3/2011
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-011-0081-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases

Targeting Bone as a Therapy for Myeloma

The PCa Tumor Microenvironment

Introduction to the Special Issue on The Microenvironment of Bone Metastasis

The Immune Microenvironment of Myeloma

Bone Anabolic Agents for the Treatment of Multiple Myeloma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer